Subject(s)
Bacterial Infections/blood , Hematopoietic Stem Cell Transplantation , Neutropenia/blood , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Adult , Aged , Allografts , Bacterial Infections/microbiology , Female , Humans , Male , Middle Aged , Neutropenia/etiology , Neutropenia/microbiology , Retrospective StudiesABSTRACT
Despite the availability of newer classes of antibiotics, infection with multi-drug-resistant bacteria is a serious problem. To suppress the appearance of multi-drug-resistant bacteria and to avoid severe infection derived from febrile neutropenia (FN), we conducted cycling the administration of antibiotics for FN in patients with hematological malignancy. The treatment protocol consisted of the administration of four antibiotics each for 3 months in 1 year. The above regimen was repeated for 4 years. A total of 193 patients were registered in the protocol. The mean duration of the administration of cycling antibiotics was 5.9 days (range: 1-16 days). The frequency of FN before the study and during the study was unchanged until the third year, but decreased significantly in the fourth year. The frequency of detection of multi-drug-resistant bacteria in the first year was the same as that before the study was started, but dramatically decreased after the second year. Bacteriological treatment success rates were similar in each trimester and each year. The effective rate was not statistically different in each trimester and each year. We conclude that cycling the administration of antibiotics in patients with FN is useful for suppressing the appearance of multi-drug-resistant bacteria and for obtaining excellent clinical efficacy.
Subject(s)
Anti-Bacterial Agents/administration & dosage , Bacterial Infections/epidemiology , Fever/drug therapy , Hematologic Neoplasms/therapy , Hematopoietic Stem Cell Transplantation/adverse effects , Neutropenia/drug therapy , Adolescent , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/drug therapy , Bacterial Infections/microbiology , Drug Administration Schedule , Drug Resistance, Multiple, Bacterial/drug effects , Drug Therapy, Combination , Female , Fever/epidemiology , Humans , Japan , Male , Middle Aged , Neutropenia/epidemiology , Neutropenia/microbiology , Treatment Outcome , Young AdultABSTRACT
Although bacterial infection is a major cause of death even after reduced-intensity conditioning (RIC) for allogeneic stem cell transplantation (SCT), little is known about the epidemiology and risk factors. The incidence of bacterial infection in 43 patients who received allogeneic bone marrow transplantation (BMT) using a RIC regimen was compared with that in 68 patients who received BMT using a myeloablative conditioning regimen, and risk factors for bacterial infection were identified. Before engraftment, incidences of febrile neutropenia (FN) and documented infections (DI) were significantly decreased in RIC patients (FN: 59.5% vs. 89.6%, P<0.01, DI: 4.8% vs. 17.9%, P<0.01). However, incidence of bacterial infection was significantly increased in RIC patients in the post-engraftment phase (53.8% vs. 11.1%, log-rank, P<0.01). Blood stream was the most frequent focus of infection in both groups. In multivariate analysis, RIC and acute graft-versus-host disease were revealed to be significant risk factors for bacterial infection in this phase. In summary, risk of bacterial infection after engraftment was significantly higher in RIC patients, although infection was decreased before engraftment, and we need to develop a RIC-specific strategy against bacterial infection after RIC SCT.
Subject(s)
Bacterial Infections/etiology , Bone Marrow Transplantation/adverse effects , Transplantation Conditioning , Adolescent , Adult , Aged , Bacterial Infections/epidemiology , Bone Marrow Transplantation/mortality , Catheterization, Central Venous/adverse effects , Female , Graft vs Host Disease/etiology , Humans , Male , Middle Aged , Retrospective Studies , Risk Factors , Transplantation, HomologousSubject(s)
Bone Marrow Transplantation/adverse effects , Sarcoidosis/etiology , Transplantation, Homologous/adverse effects , Female , Fluorodeoxyglucose F18/pharmacology , Humans , Lymph Nodes/pathology , Lymphoma, Follicular/complications , Lymphoma, Follicular/therapy , Middle Aged , Prognosis , Radiopharmaceuticals/pharmacology , Remission Induction , Treatment OutcomeABSTRACT
High costs of molecule-targeted drugs, such as rituximab, ibritumomab, and tositumomab have given rise to an economical issue for treating patients with non-Hodgkin's lymphoma (NHL). Granulocyte colony-stimulating factors (G-CSFs), which are also expensive, are widely used for treating neutropenia after chemotherapy. In Japan, lenograstim at 2 microg/kg (about 100 microg/body) or filgrastim at 50 microg/m(2) (about 75 microg/body) is commonly administered for patients with NHL after chemotherapy. Therefore, cost-effectiveness is an important issue in treatment for NHL. Patients with advanced-stage NHL who needed chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or a CHOP-like regimen with or without rituximab were enrolled in this randomized cross-over trial to investigate the efficacy and safety of low-dose G-CSF. Half of the patients were administered 75 microg filgrastim in the first course after neutropenia and 50 microg lenograstim in the second course, and the other half were crossed over. Forty-seven patients were enrolled in this cross-over trial, and 24 patients completed the trial. Frequencies and durations of grade 4 leukocytopenia and neutropenia were similar in the two groups. Severe infection was rare and was observed at similar frequency. Frequencies of antibiotics use were also similar. The total cost of G-CSF (cost/drug x duration of administration) was significantly lower in patients who received 50 microg lenograstim. Hence, a low dose of lenograstim might be safe, effective and pharmaco-economically beneficial in patients with advanced-stage NHL.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Granulocyte Colony-Stimulating Factor/economics , Lymphoma, Non-Hodgkin/drug therapy , Adult , Aged , Aged, 80 and over , Cost-Benefit Analysis , Cross-Over Studies , Female , Filgrastim , Granulocyte Colony-Stimulating Factor/administration & dosage , Humans , Lenograstim , Lymphoma, Non-Hodgkin/economics , Male , Middle Aged , Neutropenia/drug therapy , Neutropenia/etiology , Recombinant Proteins/administration & dosage , Recombinant Proteins/economicsABSTRACT
A 65-year-old Japanese male was diagnosed as multiple myeloma with Bence Jones kappa type, clinical stage IIIA. His disease status reached partial remission after chemotherapy. Thereafter, he received tandem transplantation, consisting of high-dose chemotherapy with autologous stem cell transplantation (ASCT), followed by unrelated cord blood transplantation (U-CBT). U-CBT with a reduced-intensity conditioning regimen (RI-CBT) was performed in August 2003. HLA mismatch between the patient and the CBT donor was present at two serological loci (B and DR). A total nucleated CBT cell dose of 2.45 x 10(7)/kg body weight was infused on day 0. Graft-vs.-host disease (GVHD) prophylaxis consisted of cyclosporine A and short-term methotrexate. Neutrophil engraftment (>0.5 x 10(9)/l) was obtained on day 46. He developed positive cytomegalovirus antigenemia, grade II acute GVHD involving skin and liver, varicella-zoster virus infection, septic shock, hemorrhagic cystitis caused by adenovirus and acute hepatitis B virus infection after U-CBT. We retrospectively analyzed T-cell receptor (TCR) repertoire diversity and found that TCR repertoire diversity decreased continuously after U-CBT. Therefore, low-TCR repertoire diversity in this patient appears to be associated with various infections caused by immunodeficiency.
Subject(s)
Cord Blood Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cell Transplantation/adverse effects , Multiple Myeloma/therapy , T-Cell Antigen Receptor Specificity/immunology , Transplantation Chimera , Virus Diseases/immunology , Aged , Humans , Immunocompromised Host , Male , T-Lymphocytes/radiation effects , Transplantation Conditioning , Transplantation, Autologous , Virus Diseases/complicationsABSTRACT
The relationship between Helicobacter pylori infection and idiopathic thrombocytopenic purpura (ITP) has been investigated in several studies. We investigated the prevalence of H. pylori infection and the clinical effects of eradication in 22 Japanese patients with chronic ITP. H. pylori infection was found in 14 (63.6%) of the patients by histologic and culture examinations of biopsy samples obtained by gastrointestinal endoscopy. H. pylori was eradicated by proton pump inhibitors and 2 kinds of antibiotics in 13 (92.9%) of the 14 patients in whom the results of treatment could be evaluated. Five (38.4%) of those 13 patients had platelet recovery (platelet count of more than 100 x 10(9)/L and an increase of more than 30 x 10(9)/L with respect to the baseline value) after eradication. The median follow-up period was 15 months. One patient who had a complete response had a partial relapse after cessation of prednisolone treatment without any evidence of H. pylori reinfection. Another patient, in whom H. pylori was not eradicated even after 2 treatment sessions, had a partial response after treatment. A screening examination for H. pylori infection may be necessary for Japanese patients with newly diagnosed ITP. Although the exact mechanism underlying platelet recovery after H. pylori eradication is not clear, the results of this study indicated that H. pylori eradication treatment is a good option for some patients with chronic ITP.
Subject(s)
Blood Platelets/cytology , Helicobacter pylori , Purpura, Thrombocytopenic, Idiopathic/blood , Purpura, Thrombocytopenic, Idiopathic/microbiology , Adult , Aged , Cytokines/blood , Female , Helicobacter Infections/complications , Helicobacter Infections/drug therapy , Helicobacter Infections/epidemiology , Humans , Japan/epidemiology , Male , Middle Aged , Platelet Count , Prevalence , Purpura, Thrombocytopenic, Idiopathic/drug therapyABSTRACT
In the present study, we investigated the inhibitory natural killer cell receptor (NKR) expression of CD94/NKG2A on PBMC after allogeneic bone marrow transplantation (BMT). The proportion of CD94 expression on PBMC was higher in patients without chronic graft-versus-host disease (cGVHD) and also in cGVHD patients with good response to conventional immunosuppressive therapy than in cGVHD patients with poor response. Also, the proportions of CD94+/CD3+ cells and CD94+/CD8+ cells were higher in cGVHD patients showing good response. In addition, the proportion of NKG2A-expressing cells was higher in patients without cGVHD than in patients with cGVHD. Therefore, chronic allostimulation after allo-BMT may augment the proportion of CD94/NKG2A-positive cells, and these cells may play some role in the regulation of alloresponse in some patients.
Subject(s)
Antigens, CD/metabolism , Lectins, C-Type , Leukocytes, Mononuclear/immunology , Membrane Glycoproteins/metabolism , Transplantation, Homologous/immunology , Bone Marrow Transplantation/immunology , CD3 Complex , CD8-Positive T-Lymphocytes , Case-Control Studies , Graft vs Host Disease/blood , Graft vs Host Disease/immunology , Hematologic Neoplasms/blood , Hematologic Neoplasms/complications , Hematologic Neoplasms/therapy , Humans , Killer Cells, Natural/cytology , Killer Cells, Natural/metabolism , NK Cell Lectin-Like Receptor Subfamily C , NK Cell Lectin-Like Receptor Subfamily D , Receptors, Immunologic/metabolism , Receptors, Natural Killer Cell , T-Lymphocytes , Treatment OutcomeABSTRACT
We report a case of bone marrow infarction in a 20-year-old woman with acute lymphocytic leukemia (ALL) who underwent unrelated bone marrow transplantation (BMT). Hematopoietic engraftment occurred on day 9 and, thereafter, the patient developed acute dermal and hepatic graft-versus-host disease (GVHD). She also experienced severe arthralgia in her knee joints on day 21. Immunosuppressive therapy with prednisolone (PSL) for acute GVHD was given, and the arthralgia improved rapidly, correlating with the improvement in dermal and hepatic GVHD. Based on the laboratory findings and analysis of magnetic resonance images, she was diagnosed as having bone marrow infarction. The cause of the bone marrow infarction was thought to be acute GVHD-related microangiopathy.
Subject(s)
Bone Marrow Transplantation/adverse effects , Bone Marrow/blood supply , Graft vs Host Disease/complications , Infarction/etiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Adult , Arthralgia/diagnosis , Arthralgia/etiology , Female , Humans , Infarction/diagnosis , Magnetic Resonance Imaging , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapyABSTRACT
We report a 46-year-old man suffering from angiocentric lymphoma of the skin. On admission, he had atypical cells rich in basophilic granules in the bone marrow and peripheral blood, in addition to skin eruptions and bone marrow dysplasia. Immediately after diagnosis, the patient was treated with multidrug combination chemotherapy. At first, the chemotherapy markedly relieved the skin eruption and bone marrow dysplasia, and atypical cells in the bone marrow and peripheral blood disappeared rapidly. However, the disease gradually became resistant to chemotherapy, resulting in a gradual deterioration of the skin eruption and bone marrow dysplasia, and reappearance of atypical cells. The levels of serum cytokines such as interleukin-4 and interleukin-6, and of soluble interleukin-2 receptor correlated well with the disease states. These results suggest that the lymphoma cells directly or indirectly induce the production of these cytokines and that a dysregulated cytokine network, which might be caused by lymphoma cells, induces an increase in atypical cells.
Subject(s)
Bone Marrow/pathology , Lymphoma, Non-Hodgkin/pathology , Myelodysplastic Syndromes/pathology , Skin Neoplasms/pathology , Cytokines/blood , Humans , Lymphoma, Non-Hodgkin/blood , Male , Middle Aged , Myelodysplastic Syndromes/blood , Receptors, Interleukin-2/blood , Skin Neoplasms/bloodABSTRACT
A 34-year-old male suffered from an allergic reaction after inhalation of decontaminating drugs for BMT. Clinical challenge tests were undertaken to determine the causal drug. It was found that vancomycin hydrochloride (VCM) repeatedly induced dyspnea, fever, hypoxia, eosinophilia, and elevation of CRP. Therefore, clindamycin (CLDM) was used instead of VCM for decontamination of patient respiratory tract. Although complete decontamination of the respiratory tract was not achieved during the leukocytopenic period, BMT was successful, and there were no life-threatening infectious complications. Although inhaled VCM-induced allergic reaction may be a very rare complication in the BMT setting, careful clinical attention should be paid to such patients.